Gaël Ennequin, Benjamin Buchard, Bruno Pereira, Line Bonjean, Daniel Courteix, Bruno Lesourd, Robert Chapier, Philippe Obert, Agnes Vinet, Guillaume Walther, Marek Zak, Reza Bagheri, Chris U Ugbolue, Armand Abergel, Frédéric Dutheil, David Thivel
{"title":"Noninvasive biomarkers of non-alcoholic fatty liver disease in patients with metabolic syndrome: insights from the RESOLVE Study.","authors":"Gaël Ennequin, Benjamin Buchard, Bruno Pereira, Line Bonjean, Daniel Courteix, Bruno Lesourd, Robert Chapier, Philippe Obert, Agnes Vinet, Guillaume Walther, Marek Zak, Reza Bagheri, Chris U Ugbolue, Armand Abergel, Frédéric Dutheil, David Thivel","doi":"10.23736/S2724-5985.22.03139-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The aim of the present study was to evaluate: 1) the presence of liver steatosis using Fatty Liver Index (FLI), Hepatic Steatosis Index (HSI) and Liver Fat Score (LFS) in patients suffering from metabolic syndrome (MS); and 2) the association of FLI, HSI and LFS with the cardiometabolic risks.</p><p><strong>Methods: </strong>A total of 91 patients with MS (39 men, 52 women) and 44-age matched healthy subjects (control; 23 men and 21 women) were enrolled in the study. A continuous cardiometabolic score (MetsScore) and the noninvasive tests of hepatic steatosis were calculated for comparison and association analysis.</p><p><strong>Results: </strong>Liver steatosis was detected in 86%, 84% and 80% of people diagnosed with MS using FLI, HSI and LFS respectively and MetsScore increases with FLI severity (P<0.05). Also, FLI and LFS were positively associated with MetsScore (P<0.01 and P<0.05 respectively) but not HSI. Multivariate linear regression models revealed that FLI has a stronger association with MetsScore compared with HSI and LFS (P<0.001).</p><p><strong>Conclusions: </strong>FLI is associated with the severity of MS and represent a good indicator to assess the relation between liver steatosis and a cardiometabolic disorders in clinical routine.</p>","PeriodicalId":18653,"journal":{"name":"Minerva gastroenterology","volume":" ","pages":"494-503"},"PeriodicalIF":3.0000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Minerva gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.23736/S2724-5985.22.03139-4","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/2/10 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The aim of the present study was to evaluate: 1) the presence of liver steatosis using Fatty Liver Index (FLI), Hepatic Steatosis Index (HSI) and Liver Fat Score (LFS) in patients suffering from metabolic syndrome (MS); and 2) the association of FLI, HSI and LFS with the cardiometabolic risks.
Methods: A total of 91 patients with MS (39 men, 52 women) and 44-age matched healthy subjects (control; 23 men and 21 women) were enrolled in the study. A continuous cardiometabolic score (MetsScore) and the noninvasive tests of hepatic steatosis were calculated for comparison and association analysis.
Results: Liver steatosis was detected in 86%, 84% and 80% of people diagnosed with MS using FLI, HSI and LFS respectively and MetsScore increases with FLI severity (P<0.05). Also, FLI and LFS were positively associated with MetsScore (P<0.01 and P<0.05 respectively) but not HSI. Multivariate linear regression models revealed that FLI has a stronger association with MetsScore compared with HSI and LFS (P<0.001).
Conclusions: FLI is associated with the severity of MS and represent a good indicator to assess the relation between liver steatosis and a cardiometabolic disorders in clinical routine.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
